Life-changing therapies

Innovative medicines pipeline
Macrocycle discovery platform
Collaborate with Polyphor

Latest news

• Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.

• Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.

See all news

Meet us at

May 20-22, 2019	UBS Global Healthcare Conference, New York
February 25-26, 2019	12th Annual European Life Science CEO Forum, Zurich

Event calendar

Innovative medicines pipeline

Antibiotics

Murepavadin (POL7080) – Pseudomonas infections

Phase III

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

OMPTA platform –  targeting Gram-negative resistant pathogens

 

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

CXCR4 antagonist

Balixafortide (POL6326) – for novel immune-oncology agent for combination therapy

Fast Track Designation granted by FDA

Phase III

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Inhaled elastase inhibitor

POL6014 – Cystic Fibrosis

Outlicensed to Santhera Pharmaceuticals 14.02.2018

Phase I

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Macrocycle discovery platform

New modalities to address challenging biological targets

Learn more